The proof-of-concept open-label study evaluated the safety and tolerability, function of regulatory T cells (Tregs), biomarkers, and preliminary efficacy (as measured by the ALSFRS-R scale) of COYA ...
First clinical development program in sporadic ALS patients to show potential to restore STATHMIN-2 expression, a statistically significant effect on a neurofilament biomarker, and an overall trend of ...
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
Data demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) at 24 weeks (6 months) and a consistent reduction in inflammation, oxidative stress, and enhanced ...
The image above describes the changes in the mean scores for the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) for ALS patients treated with CL2020. The arrowheads indicate ...
The image above describes the changes in the mean scores for the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) for ALS patients treated with CL2020. The arrowheads indicate ...
Please provide your email address to receive an email when new articles are posted on . Accelerometers showed a slower rate of decline vs. ALSFRS-R scores, with strong correlation in motor domains.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results